In yesterday’s Wall Street session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares traded at $18.41, up 2.22% from the previous session.
TEVA stock price is now 5.37% away from the 50-day moving average and 27.49% away from the 200-day moving average. The market capitalization of the company currently stands at $20.86B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $20, Argus recently Upgraded its rating from Hold to Buy for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On March 08, 2024, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $14, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Daniell Richard, Exec. VP, European Commercial sold 98,943 shares of the company’s stock on Aug 12 ’24. The stock was sold for $1,711,447 at an average price of $17.30. Upon completion of the transaction, the Exec. VP, European Commercial now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 09 ’24, EVP, Business Development Grant Angus sold 4,065 shares of the business’s stock. A total of $70,243 was realized by selling the stock at an average price of $17.28. This leaves the insider owning 8,848 shares of the company worth $0.16 million. A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $8.06 and a high of $19.08. As of last week, the company has a debt-to-equity ratio of 2.98, a current ratio of 0.89, and a quick ratio of 0.59. The fifty day moving average price for TEVA is $17.5038 and a two-hundred day moving average price translates $14.48275 for the stock.
The latest earnings results from Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was released for 2024-06-30. The net profit margin was -2.72% and return on equity was -6.61% for TEVA. The company reported revenue of $4.16 billion for the quarter, compared to $3.88 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.37 percent. For the current quarter, analysts expect TEVA to generate $4.11B in revenue.
